nach oben

CNS Drugs

Erschienen in:

01.04.2012 | Adis Drug Clinical Q&A

Buprenorphine 5,10 and 20 μg/h Transdermal Patch: A Guide to Its Use in Chronic Non-Malignant Pain

verfasst von: Greg L. Plosker, Katherine A. Lyseng-Williamson

Erschienen in: CNS Drugs | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Buprenorphine lower-dose (5, 10 and 20 mg/h) transdermal patches, which are administered once every 7 days, are indicated in the management of chronic non-malignant pain. This review focuses on the labelling of this formulation (BuTrans®) in the EU. The analgesic efficacy of transdermal buprenorphine in patients with osteoarthritis of the hip and/or knee has been demonstrated to be equivalent to sublingual buprenorphine, noninferior to prolonged-release tramadol and generally superior to a matching transdermal placebo patch. When used together with regularly scheduled oral paracetamol (acetaminophen), transdermal buprenorphine was noninferior to codeine plus paracetamol. Transdermal buprenorphine has also shown analgesic efficacy in patients with chronic non-malignant pain of various causes.

Kumar N. WHO normative guidelines on pain management: report of a delphi study to determine the need for guidelines and to identify the number and topics of guidelines that should be developed by WHO. Geneva: World Health Organization, 2007 Jun

Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009 Feb; 10(2): 113–30PubMedCrossRef

Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005; 6(2): 107–12PubMedCrossRef

Pergolizzi J, Boger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 2008; 8(4): 287–313PubMedCrossRef

Scoping document for WHO treatment guidelines on chronic non-malignant pain in adults. Geneva: World Health Organization, 2008 Oct

BuTrans 5, 10 and 20ug/h transdermal patch: EU summary of product characteristics. Cambridge, UK: Napp Pharmaceuticals Limied, 2010 Mar 11

Plosker GL. Buprenorphine 5, 10 and 20mg/h transdermal patch: a review of its use in the management of chronic non-malignant pain. Drugs 2011; 71(18): 2491–509PubMedCrossRef

Breivik H, Ljosaa TM, Stengaard-Pedersen K, et al. A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naive to potent opioids. Scand J Pain 2010; 1(3): 122–41CrossRef

James IG, O’Brien CM, McDonald CJ. A randomized, double-blind, double-dummy comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. J Pain Symptom Manage 2010 Aug; 40(2): 266–78PubMedCrossRef

10.

Karlsson M, Berggren AC. Efficacy and safety of lowdose transdermal buprenorphine patches (5, 10, and 20microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200mg) in patients with chronic osteoarthritis pain: a 12-week, randomized, open-label, controlled, parallelgroup noninferiority study. Clin Ther 2009 Mar; 31(3): 503–13PubMedCrossRef

11.

Munera C, Drehobl M, Sessler NE, et al. A randomized, placebo-controlled, double-blinded, parallel-group, 5-week study of buprenorphine transdermal system in adults with osteoarthritis. J Opioid Manag 2010; 6(3): 193–202PubMedCrossRef

12.

Conaghan PG, O’Brien CM, Wilson M, et al. Transdermal buprenorphine plus oral paracetamol vs an oral codeineparacetamol combination for osteoarthritis of hip and/or knee: a randomised trial. Osteoarthritis Cartilage 2011; 19: 930–8PubMedCrossRef

13.

Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. Clin Ther 2010 May; 32(5): 844–60PubMedCrossRef

14.

Gordon A, Rashiq S, Moulin DE, et al. Buprenorphine transdermal system for opioid therapy in patients with chronic low back pain. Pain Res Manag 2010; 15(3): 169–78PubMed

15.

Landau CJ, Carr WD, Razzetti AJ, et al. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenanceof-analgesia study. Clin Ther 2007 Oct; 29(10): 2179–93PubMedCrossRef

16.

American College of Rheumatology. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) [online]. Available from URL: http://www.rheumatology.org/practice/clinical/clinicianresearchers/outcomes-instrumentation/WOMAC.asp [Accessed 2011 Dec 22]

17.

Schutter U, Ritzdorf I, Heckes B. 7-day buprenorphine patch-an option when therapy with tramadol or tilidine/ naloxone is inadequate: results of a non-intervention study [in German]. MMW-Fortschr Med 2010; 152(II): 62–9PubMed

18.

Böhme K, Heckes B, Thomitzek K. Seven-day buprenorphine transdermal patch in multimorbid patients on longterm ibuprofen or diclofenac [in German]. MMW-Fortschr Med 2010; 152(IV): 125–32

19.

Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth 2006 May; 96(5): 627–32PubMedCrossRef

20.

Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain 2009 Mar; 13(3): 219–30PubMedCrossRef

21.

Dahan A. Opioid-induced respiratory effects: new data on buprenorphine. Palliat Med 2006; 20 Suppl. 1: S3–8PubMedCrossRef

22.

Butrans (buprenorphine) transdermal system for transdermal administration: US prescribing information. Stamford (CT): Purdue Pharma L.P., 2010 Jun

Titel: Buprenorphine 5,10 and 20 μg/h Transdermal Patch: A Guide to Its Use in Chronic Non-Malignant Pain
verfasst von: Greg L. Plosker
Katherine A. Lyseng-Williamson
Publikationsdatum: 01.04.2012
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 4/2012
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/11208360-000000000-00000

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Beneficial and Adverse Psychotropic Effects of Antiepileptic Drugs in Patients with Epilepsy

The Role of Antidepressants in the Management of Fibromyalgia Syndrome

Ziprasidone and the Corrected QT Interval

Role of Ghrelin in the Pathophysiology of Eating Disorders

Cost Effectiveness of Lacosamide in the Adjunctive Treatment of Patients with Refractory Focal Epilepsy in Belgium

Pharmacological Revascularization of Acute Ischaemic Stroke